PT Kabelindo Murni Tbk (IDX:KBLM)
Indonesia · Delayed Price · Currency is IDR 324.00
-4.00 (-1.23%)
Aug 5, 2025, 3:49 PM WIB
Marinus Pharmaceuticals Income Statement
Financials in millions IDR. Fiscal year is January - December.
Millions IDR. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2016 - 2020 |
| 2,004,926 | 1,988,595 | 1,648,519 | 1,514,908 | 1,214,204 | 883,823 | Upgrade | |
Revenue Growth (YoY) | 17.31% | 20.63% | 8.82% | 24.77% | 37.38% | -23.09% | Upgrade |
Cost of Revenue | 1,842,317 | 1,852,128 | 1,560,184 | 1,448,700 | 1,192,351 | 836,448 | Upgrade |
Gross Profit | 162,609 | 136,467 | 88,334 | 66,208 | 21,853 | 47,375 | Upgrade |
Selling, General & Admin | 31,225 | 33,499 | 38,573 | 36,591 | 38,953 | 38,062 | Upgrade |
Other Operating Expenses | 6,103 | 3,283 | -3,758 | -15,741 | -17,113 | -5,294 | Upgrade |
Operating Expenses | 37,328 | 36,782 | 34,815 | 20,849 | 21,840 | 32,768 | Upgrade |
Operating Income | 125,281 | 99,685 | 53,519 | 45,359 | 13.28 | 14,607 | Upgrade |
Interest Expense | - | - | -11,436 | -10,133 | -11,189 | -4,695 | Upgrade |
Interest & Investment Income | 1,013 | 1,240 | 354.39 | 274.4 | 247.22 | 310.59 | Upgrade |
Currency Exchange Gain (Loss) | 99.34 | 212.75 | 96.71 | 72.15 | 78.24 | -85.5 | Upgrade |
Other Non Operating Income (Expenses) | 1,080 | -425 | -425 | -429.5 | -405 | -415 | Upgrade |
EBT Excluding Unusual Items | 127,473 | 100,713 | 42,109 | 35,143 | -11,255 | 9,722 | Upgrade |
Gain (Loss) on Sale of Assets | 297.52 | 297.52 | - | - | 1,830 | - | Upgrade |
Asset Writedown | -16.77 | -16.77 | - | - | -1,617 | - | Upgrade |
Other Unusual Items | - | - | - | - | - | -592.02 | Upgrade |
Pretax Income | 127,754 | 100,993 | 42,109 | 35,143 | -11,042 | 9,130 | Upgrade |
Income Tax Expense | 29,433 | 23,619 | 11,343 | 4,645 | 1,958 | 2,566 | Upgrade |
Earnings From Continuing Operations | 98,321 | 77,375 | 30,766 | 30,497 | -13,000 | 6,564 | Upgrade |
Net Income to Company | 98,321 | 77,375 | 30,766 | 30,497 | -13,000 | 6,564 | Upgrade |
Net Income | 98,321 | 77,375 | 30,766 | 30,497 | -13,000 | 6,564 | Upgrade |
Net Income to Common | 98,321 | 77,375 | 30,766 | 30,497 | -13,000 | 6,564 | Upgrade |
Net Income Growth | 313.65% | 151.50% | 0.88% | - | - | -83.02% | Upgrade |
Shares Outstanding (Basic) | 1,120 | 1,120 | 1,120 | 1,120 | 1,120 | 1,120 | Upgrade |
Shares Outstanding (Diluted) | 1,120 | 1,120 | 1,120 | 1,120 | 1,120 | 1,120 | Upgrade |
EPS (Basic) | 87.79 | 69.08 | 27.47 | 27.23 | -11.61 | 5.86 | Upgrade |
EPS (Diluted) | 87.79 | 69.08 | 27.47 | 27.23 | -11.61 | 5.86 | Upgrade |
EPS Growth | 313.65% | 151.50% | 0.88% | - | - | -83.02% | Upgrade |
Free Cash Flow | -73,869 | -28,616 | 110,329 | 67,465 | -30,355 | 49,298 | Upgrade |
Free Cash Flow Per Share | -65.95 | -25.55 | 98.51 | 60.24 | -27.10 | 44.02 | Upgrade |
Dividend Per Share | 20.000 | 20.000 | 8.000 | 8.000 | - | 5.000 | Upgrade |
Dividend Growth | 150.00% | 150.00% | - | - | - | -50.00% | Upgrade |
Gross Margin | 8.11% | 6.86% | 5.36% | 4.37% | 1.80% | 5.36% | Upgrade |
Operating Margin | 6.25% | 5.01% | 3.25% | 2.99% | 0.00% | 1.65% | Upgrade |
Profit Margin | 4.90% | 3.89% | 1.87% | 2.01% | -1.07% | 0.74% | Upgrade |
Free Cash Flow Margin | -3.68% | -1.44% | 6.69% | 4.45% | -2.50% | 5.58% | Upgrade |
EBITDA | 148,466 | 122,702 | 76,534 | 67,411 | 19,382 | 34,163 | Upgrade |
EBITDA Margin | 7.41% | 6.17% | 4.64% | 4.45% | 1.60% | 3.86% | Upgrade |
D&A For EBITDA | 23,185 | 23,017 | 23,015 | 22,053 | 19,369 | 19,557 | Upgrade |
EBIT | 125,281 | 99,685 | 53,519 | 45,359 | 13.28 | 14,607 | Upgrade |
EBIT Margin | 6.25% | 5.01% | 3.25% | 2.99% | 0.00% | 1.65% | Upgrade |
Effective Tax Rate | 23.04% | 23.39% | 26.94% | 13.22% | - | 28.11% | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.